Investments

Founded in 1921 and based in Mendrisio, Sintetica is a Swiss pharmaceutical company specializing in research, manufacturing and marketing of sterile injectable solutions, including anaesthetic, analgesic and adrenergic drugs, which are distributed in more than 45 countries. Sintetica operates with an agile distribution model based on two channels: direct sales to hospitals (in Switzerland, Germany, Austria, the United Kingdom and Ireland) and strategic partnerships globally based on license agreements. With 280 employees and manufacturing plants in Mendrisio and Couvet, the company is widey recognised for its innovative human-centred organisational model and its distinctive go-to-market philosophy based on 360-degree respect and the high quality of its products.

Inula Group was created following the merger of Pranarôm and HerbalGem, two pioneering laboratories specialized in natural therapies, founded in 1985 and 1986 respectively. Inula is a key player in the herbal remedies market, specializing in fast growing sub-sectors such as aromatherapy, gemmotherapy and Bach flowers, through three brands: Pranarôm, HerbalGem and Biofloral. Thanks to its strong scientific approach and the quality of its products, the Group has experienced significant growth over the past years and is now present in more than 25 countries, with leading positions in France, Belgium, Spain, Italy and the USA.

Neopharmed Gentili represents the spin-off of the primary care business of Mediolanum Farmaceutici Group and is a leading pharmaceutical company in the Italian market focused on branded prescription drugs in cardiovascular, neurology and allergo-respiratory therapeutic areas, with a portfolio of off-patent and mostly proprietary products. Its flexible and asset-light business model makes Neopharmed Gentili an attractive commercial platform with a proprietary, reliable, and specialized sales force of over 400 pharma representatives.

Founded in 1993 from the takeover of a Sanofi facility in Amiens, Unither Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO). With annual revenues of +250 M€ and a team of more than 1,200 professionals, Unither Pharmaceuticals operates 6 manufacturing sites and 1 R&D center in France, USA and Brazil.

Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies. Envision currently has ten offices, three in the United Kingdom, five in the United States, two in Asia Pacific, and employs around 450 team members.

Laboratoires Anios is present in more than 80 countries with different business units addressing notably the healthcare segment, through hospitals, clinics, and healthcare professionals. Laboratoires Anios is also present in food-processing, cosmetics, and pharmaceutics industries, as well as in the communities linked to accommodation and catering. International build up acquisitions will form the heart of the company’s growth strategy, which will be supported by ongoing investment, notably in R&D.